Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Epidemiology

Internal Medicine

Public Health, Environmental And Occupational Health

(+)-Naloxone

Show all topics

DOI

10.1016/s0140-6736(17)32812-x

Other Formats

PDF